Company intelligence / Profile preview
Valo Therapeutics
Helsinki, Finlandvalotx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Valo Therapeutics’ lead product, PeptiCRAd‑1—comprising the proprietary virus VALO-D102 coated with MAGE-A3 and NY‑ESO‑1 peptides—is in Phase I clinical trials as an intratumoral vaccine for solid tumors such as synovial sarcoma. Early results focus on safety and immune response; expanded funding will support further clinical development across multiple countries. The company’s pipeline also includes technologies to rapidly identify tumor neoantigens to enable personalized immunotherapies.[3][7][8][9]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Oncolytic viruses (adenoviruses and enveloped viruses)Peptide vaccines (tumor antigen-coated viral vectors)Vaccine vectors
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Texcell – research collaboration to evaluate immune responses to lead product in clinical study[9].University of Helsinki – academic origin of core technologies and ongoing collaborations[10].
Beyond the preview
Go deeper on Valo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Valo Therapeutics.